What medications are effective for both psoriasis and inflammatory bowel disease?

Medications Effective for Both Psoriasis and IBD

TNF inhibitors—specifically infliximab and adalimumab—are the preferred first-line biologic therapies for patients with both psoriasis and inflammatory bowel disease, as they have demonstrated efficacy in treating both conditions simultaneously. 1, 2, 3

Primary Treatment Options

TNF Inhibitors (First-Line)

• Infliximab is FDA-approved and effective for psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, making it an excellent choice when treating both conditions concurrently 1, 3
• Adalimumab similarly demonstrates efficacy across all four indications (psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease) 1, 3
• Both agents work by targeting shared inflammatory pathways (TNF-alpha) that drive disease activity in both psoriasis and IBD 4
• Biosimilars of infliximab and adalimumab are supported due to equivalent effectiveness and safety at reduced costs 2

Alternative TNF Inhibitors

• Certolizumab pegol is effective for psoriatic arthritis and Crohn's disease (but not ulcerative colitis) 2, 3
• Golimumab is specifically recommended for ulcerative colitis with axial spondyloarthritis 2

Second-Line Options

IL-12/23 Inhibitor

• Ustekinumab is an excellent alternative that is FDA-approved for both Crohn's disease and psoriasis, with demonstrated effectiveness in phase 3 trials for IBD, including in patients who failed TNF inhibitors 1, 3
• Ustekinumab has shown efficacy in psoriasis, psoriatic arthritis, and Crohn's disease 3
• This agent can be considered when TNF inhibitors are not suitable or have failed 1

JAK Inhibitors (After TNF Failure)

• Tofacitinib and upadacitinib are FDA-approved for moderate-to-severe ulcerative colitis and should be reserved as second-line therapy after TNF inhibitor failure 1, 2

Critical Medications to AVOID

IL-17 Inhibitors (Absolute Contraindication)

• Secukinumab, ixekizumab, and brodalumab must be strictly avoided in patients with IBD or at risk for IBD, as they can cause new-onset inflammatory bowel disease or exacerbate existing disease 1, 5, 6
• The American Academy of Dermatology explicitly recommends avoiding IL-17 inhibitors in IBD patients (Strength of Recommendation C, Level of Evidence I) 1
• Clinical trials have demonstrated that IL-17 inhibitors can exacerbate Crohn's disease 1, 3
• These agents (etanercept, secukinumab, brodalumab, ixekizumab) have efficacy in psoriasis and psoriatic arthritis but may induce or worsen IBD 3

Etanercept

• Etanercept should not be used due to its ineffectiveness in active Crohn's disease and potential to trigger new-onset Crohn's disease 2

Vedolizumab

• Vedolizumab is not recommended for IBD with psoriasis because it lacks efficacy for dermatologic manifestations despite being effective for IBD 2

Combination Therapy Considerations

• TNF inhibitors combined with thiopurines or methotrexate show superior efficacy for ulcerative colitis remission compared to monotherapy, and this combination approach can benefit both the UC and psoriasis components 1
• Methotrexate has demonstrated efficacy for both psoriasis and IBD and may be used in combination with biologic agents 1

Essential Screening and Monitoring

Pre-Treatment Screening

• Screen all psoriasis patients for IBD symptoms before starting systemic therapy, as the prevalence of ulcerative colitis is 1.64-1.91 times higher and Crohn's disease is 2.49 times higher in psoriasis patients versus controls 1
• Red-flag symptoms requiring immediate gastroenterology referral include: chronic diarrhea lasting ≥3 months, nocturnal bowel movements, rectal bleeding not from hemorrhoids, persistent abdominal pain, perianal fistula/abscess, and unintentional weight loss 1

During Treatment Monitoring

• Monitor for new or worsening gastrointestinal symptoms during psoriasis treatment, warranting immediate gastroenterology referral (Strength of Recommendation A) 1
• Patients with psoriatic arthritis, especially those with axial involvement, exhibit higher incidence and prevalence of IBD than patients with skin-only psoriasis 1

Common Pitfalls to Avoid

• Never prescribe IL-17 inhibitors to patients with known IBD or suspicious gastrointestinal symptoms—this is the most critical error to avoid 1, 5, 6
• Do not assume that all biologics effective for psoriasis will be safe for IBD—the IL-17 pathway demonstrates this critical distinction 4, 5
• If paradoxical psoriasiform eruptions develop while on TNF inhibitor therapy for UC, first attempt to add standard psoriasis treatments (topical corticosteroids, vitamin D analogues) while continuing the TNF inhibitor, as this achieves complete or partial skin clearance in 90% of cases 1